Nektar Therapeutics Company Profile (NASDAQ:NKTR)

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Nektar Therapeutics (NASDAQ:NKTR) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.04. The firm had revenue of $34.60 million for the quarter, compared to the consensus estimate of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The firm's revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.36) EPS. View Nektar Therapeutics' Earnings History.

Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Nektar Therapeutics.

10 analysts have issued twelve-month target prices for Nektar Therapeutics' stock. Their forecasts range from $20.00 to $33.00. On average, they anticipate Nektar Therapeutics' stock price to reach $26.33 in the next year. View Analyst Ratings for Nektar Therapeutics.

Here are some recent quotes from research analysts about Nektar Therapeutics stock:

• 1. According to Zacks Investment Research, "Nektar reported wider-than-expected loss in the second quarter of 2017 with revenue missing estimates. The launch of its drugs, Movantik and Adynovate, has been on track with both the products performing impressively. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone plus royalties for Movantik under the license agreement with AstraZeneca, which might substantially boost its financial position. Also, its recent co-development deal with Lilly for NKTR-358 is also encouraging. However, Nektar relies heavily on partners for revenues. Partnership-related setbacks may weigh heavily on the company, while disappointing products sales could leave an adverse impact on its financial results. Nektar also has a promising pipeline, with several updates lined up for the next several quarters. The company’s shares have outperformed the industry in the year so far." (8/11/2017)
• 2. BTIG Research analysts commented, "Nektar announced positive results from the Phase 3 SUMMIT-07 study of NKTR-181, its novel, proprietary, abuse-resistant opioid for pain. NKTR- 181 met all important primary and secondary efficacy endpoints in the 610- patient study, and the molecule appeared well tolerated, materially derisking the program. At its primary endpoint at week 12 postrandomization, average pain scores increased 1.46 points on the Numeric Rating Scale with placebo, vs. 0.92 points for NKTR-181 (p=0.0019); other secondary endpoints were also as positive. NKTR-181 has been FastTracked, a rarity for an opioid, and with this highly positive study in hand, there is a possibility for rapid progression of NKTR-181, and a material partnership. With 181's success, and with the potential for additional meaningful catalysts near-term, we raise our NKTR price target to $27." (3/21/2017)
• 3. Jefferies Group LLC analysts commented, "The unexpected Ph 3 success for '181 brings this once very promising mu-opioid analgesic asset back to life. In our view, it could become NKTR's largest and most profitable product as it squarely addresses the 'opioid epidemic'. Mgt hopes to partner the drug by YE. We believe '181 could bring significant value (modeling 30% royalties and $250M+ in milestones) to the company as early as 2020. With this asset now unencumbered, NKTR now fits our M&A thesis." (3/21/2017)
• 4. Aegis analysts commented, "NKTR-181 met its primary endpoint in the phase III Summit-07 trial - increase Price Target to $25. Yesterday morning, Netkar Therapeutics announced that NKTR-181 met its primary endpoint of mean change in weekly average numeric rating scale (NRS) pain score for the randomized, double-blind treatment period from the end of the open-label titration period (baseline) to week 12. Average pain scores measured at week 12 from baseline increased 1.46 for placebo vs. 0.92 for NKTR-181 (p=0.0019). We had not previously factored in revenue from NKTR-181 into our price target. As a result of the positive phase III results, we now include such revenue under partnering assumptions in the US and raise our price target from $21 to $24." (3/20/2017)

Some companies that are related to Nektar Therapeutics include United Therapeutics Corporation (UTHR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Exact Sciences Corporation (EXAS), PAREXEL International Corporation (PRXL), Bio-Techne Corp (TECH), ACADIA Pharmaceuticals (ACAD), WuXi PharmaTech (Cayman) (WX), Portola Pharmaceuticals (PTLA), INC Research Holdings (INCR), Sage Therapeutics (SAGE), Puma Biotechnology (PBYI), FibroGen (FGEN), Ligand Pharmaceuticals Incorporated (LGND), Ironwood Pharmaceuticals (IRWD), Intrexon Corporation (XON), Blueprint Medicines Corporation (BPMC) and Foundation Medicine (FMI).

Nektar Therapeutics' management team includes the folowing people:

• Robert B. Chess, Independent Chairman of the Board
• Howard W. Robin, President, Chief Executive Officer, Director
• Gilbert M. Labrucherie J.D., Chief Financial Officer, Senior Vice President
• John L. Nicholson, Chief Operating Officer, Senior Vice President
• Jillian B. Thomsen, Senior Vice President - Finance, Chief Accounting Officer
• Stephen K. Doberstein Ph.D., Senior Vice President, Chief Scientific Officer
• Ivan Philip Gergel M.D., Senior Vice President - Drug Development & Chief Medical Officer
• Maninder Hora Ph.D., Senior Vice President - Pharmaceutical Development and Manufacturing Operations
• R. Scott Greer, Independent Director
• Joseph J. Krivulka, Independent Director

Nektar Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.03%), Vanguard Group Inc. (9.03%), State Street Corp (2.82%), Westfield Capital Management Co. LP (2.43%), Bank of New York Mellon Corp (1.38%) and Northern Trust Corp (1.25%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield, Stephen K Doberstein and Susan Wang. View Institutional Ownership Trends for Nektar Therapeutics.

Nektar Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., First Trust Advisors LP, Westfield Capital Management Co. LP, TIAA CREF Investment Management LLC, Castleark Management LLC, Public Sector Pension investment Board and California State Teachers Retirement System. Company insiders that have sold Nektar Therapeutics stock in the last year include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.

Nektar Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, PointState Capital LP, State Street Corp, Numeric Investors LLC, Vanguard Group Inc., Rice Hall James & Associates LLC, First Light Asset Management LLC and UBS Asset Management Americas Inc.. Company insiders that have bought Nektar Therapeutics stock in the last two years include R Scott Greer and Roy A Whitfield. View Insider Buying and Selling for Nektar Therapeutics.

Shares of Nektar Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Nektar Therapeutics stock can currently be purchased for approximately $18.04.